SAN FRANCISCO, CA -- January 10, 2022 -- InvestorsHub NewsWire
-- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The
Company") update on its progress to kick off the new
year.
The Company has advanced its relationship and made further
investment into Ribeira Solutions' Connect2Med, a patient
engagement platform utilizing latest available technologies.
Connect2Med provides a motivating trial experience through
increased engagement and easy to use communication tools.
They have access to a dedicated trial specific portal
(patient facing app), where they can perform functions like eDiary,
ePRO and telehealth visits. The platform is FHIR compatible and
easily integrates with EHR, CTMS, CRM from major vendors in the
industry. Patients' workflow can be automated through a set
of digital workflows, with automated interventions and escalation
when needed. Sites and CROs can post upcoming trials in a
public space for all to see, boosting public awareness through
social sharing. Site owners and Sponsors have access to
impactful data, metrics and reports that allow them to make
strategic decisions to improve retention, growth, performance,
satisfaction and ROI.
In regards to Oncology Pharma's ongoing work with NanoSmart,
advancement continues to be made on the feasibility studies,
testing and initial gathering of data of nanoemulsion formulations
for dactinomycin. Early work continues to be promising with
formulations demonstrating a satisfactory level of nanoemulsion
loading and retention of dactinomycin. Studies to assess the
physical characterization of the formulations, as well as
quantitative performance measures (e.g., storage stability,
time-to-release, etc.) are currently underway. This phase of
the project is expected to be complete on schedule., with
initiation of formal IND-enabling studies anticipated to commence
later this year once the appropriate funding has been
secured. With a focus on results, the Company expects for
data to be available and ready to be shared in upcoming
announcements.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently
engaging in research and development of therapeutics for oncology
and prides itself for having a world-class Advisory Board that
keeps the Company in the forefront of developing technologies in
cancer research, biotechnology, and healthcare.
ABOUT Ribera Solutions, LLC (www.riberasolutions.com)
Ribera Solutions (CA, USA) has developed Web based Connect2Med
platform with iOS and Android mobile Apps. Ribera's mission is to
provide solutions for solving challenging problems timely through
simple, practical and economical approaches.
ABOUT NANOSMART PHARMACEUTICALS, INC.
NanoSmart® Pharmaceuticals is a privately-held California
corporation that is developing nanoparticle drug delivery
platforms, including utilization of anti-nuclear antibody (ANA) to
target existing drug therapies to areas of necrosis present in
virtually all solid cancer tumors.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships, and costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
Oncology Pharma (CE) (USOTC:ONPH)
過去 株価チャート
から 1 2025 まで 2 2025
Oncology Pharma (CE) (USOTC:ONPH)
過去 株価チャート
から 2 2024 まで 2 2025
